Regional Early-Stage Venture Capital · Private Equity, VC & Investor
Creandum
Early-stage technology venture capital firm supporting international founder growth.
Available information varies by company and source.
Profile record updated:
Company facts
- Official name
- Creandum Advisor LLP
- Entity type
- COMPANY
- Founded
- 2003
- Headquarters
- United Kingdom
- Company size
- 50–200
- Market cluster / sector
- Regional Early-Stage Venture Capital
- Market role
- Private Equity, VC & Investor
- Official website
- creandum.com
What Creandum does
The firm raises closed-end venture funds from limited partners, deploys that capital into Seed and Series A technology businesses, and supports portfolio-company growth through its investment and operating teams. It creates value through equity ownership in investees, portfolio support and exits; fund-management fees finance ongoing investment operations and carried interest links returns to realised fund performance.
Category differentiation
Creandum is a venture-capital fund adviser and investor, not an operating enterprise-software, AI-model or advertising-technology vendor. It provides capital and portfolio support rather than selling technology products to end users.
Strategic context
AI-supported assessment from the existing company research; distinguish interpretation from sourced facts.
Creandum Advisor LLP, trading as Creandum, is a private early-stage venture-capital firm investing in technology companies at Seed and Series A. Founded in 2003, it operates from London, Stockholm, Berlin and San Francisco, and supports portfolio companies’ international growth. The firm has raised $1.7 billion across its funds and invested in more than 130 companies. It earns fund-management revenue from operating venture funds and participates in investment upside through carried-interest economics. Its direct customers are institutional limited partners allocating capital to its funds, while its investee companies receive capital and operational support.
Company news briefing
Briefing updated:
European early-stage investor Creandum has led a Series A funding round for EquiLibre Technologies, elevating the Prague-based startup's valuation to over $500 million. This marks Creandum's single largest investment to date, supporting the reinforcement learning AI firm as it scales its operations in traditional financial markets.
Business model & monetisation
Creandum monetises primarily through recurring management fees charged to the venture funds it advises and through carried interest on realised investment gains. Its €500 million Creandum VII fund expands the fee-bearing capital base and its capacity to lead early-stage rounds.
- Venture-fund management fees
- Service fees charged on managed fund capital
- Carried interest
- Share of realised investment profits after fund-performance thresholds
- Investment gains attributable to fund interests
- Equity value appreciation and exits
Products & capabilities
No products with linked sources are available in this view.
Unlock Full Intelligence Profile for Creandum
Get unlimited access to corporate ownership, historical M&A transactions, verified tech stack telemetry, and live market signals in the interactive Knowledge Graph.
Verified Ownership & Corporate Hierarchy
Complete corporate hierarchy traversal, shareholder cap table history, and parent holding links sourced from regulatory filings.
360° Tech Stack & Vendor Telemetry
Technical header bidding configurations, sellers.json registry nodes, CMP disclosures, and direct programmatic supply chains.
Live Market Signals & Executive Briefings
Continuous 24/7 monitoring of material M&A deals, executive shifts, product rollouts, and hiring trends across peer entities.
Competitors & alternatives
Track competitor shifts
Receive automated telemetry on strategic moves, acquisitions, and market share shifts across Creandum's competitive landscape.
Technology venture-capital partnership investing from Seed to Growth.
Global venture capital firm focused on seed and Series A.
Global venture-capital firm funding companies from Seed through growth stages.
European venture capital firm backing technology founders.
Early-stage venture firm investing in global pre-seed and seed startups.
Side-by-side comparisons
Recent recorded signals
Dates refer to the source publication. Older entries are historical context, not evidence of a new event.
Creandum closes €668M fund for early-stage startups
Financials · Recorded impact score: 2/5
Stockholm-based venture capital firm Creandum has closed its largest fund to date, Creandum VIII, at €668 million ($750 million), surpassing its previous €500 million ($560 million) Fund VII. The fund will support approximately 30 early-stage investments from pre-Seed to Series A over the next two years, with half the capital allocated to new investments and the rest for follow-on rounds. Creandum is focusing on AI-driven opportunities, having recently invested in startups like Lovable, Olix, Modal, and Black Forest Labs. The firm has opened a new office in San Francisco, tripled its team there in the past year, and plans to expand its US presence while maintaining a generalist strategy. The fund secured commitments from about 30 institutional investors across Europe and the US.
- Creandum closed its largest fund, Creandum VIII, at €668 million ($750 million), up from €500 million Fund VII.
- The fund will support approximately 30 investments from pre-Seed to Series A, with half for new investments and half for follow-ons.
London's Ares Intelligence Raises €2.9M for AI Adoption Platform
AI in Enterprise · Recorded impact score: 2/5
London-based Ares Intelligence, a startup developing an evidence-based platform for AI transformation, has raised €2.9 million (£2.48 million) in a funding round led by Creandum and Lakestar, with participation from angel investors connected to Google DeepMind. The platform uses an AI interviewer to conduct confidential voice conversations with employees in over 70 languages, generating a prioritised roadmap for AI adoption within weeks. Founded in 2026 by Matt Falconer and Alfie Ranstead, the company addresses the challenge of where to start with AI automation. Ares counts enterprise customers across Europe and the US, including Tremonia, a Mercedes-Benz spin-out, which identified over 400 hours of manual work savings per month. The new capital will support expansion and bring its workforce intelligence approach to more businesses.
- Ares Intelligence raised €2.9 million (£2.48 million) in funding.
- The round was backed by Creandum and Lakestar, with participation from angels connected to Google DeepMind.
London Robotics Startup Machenta Raises $40M Seed
Funding · Recorded impact score: 3/5
London-based robotics startup Machenta has emerged from stealth and announced a record $40 million seed round, co-led by Creandum and Union Square Ventures — the largest seed round for a UK robotics company to date. Co-founded by Imperial College professor Edward Johns and his PhD student Vitalis Vosylius, Machenta is developing an AI model that enables robots to learn new tasks instantly after a single demonstration, eliminating the need for extensive training data. The model is trained entirely in simulation without real-world data. Johns likens the approach to 'physical vibe coding.' The company plans to use the funds to scale its technology and expand its team of about a dozen employees at its King's Cross office.
- Machenta raises $40 million in seed funding, the largest seed round for a UK robotics company.
- Seed round co-led by Creandum and Union Square Ventures.
Atlas Bio Raises $12.5M for AI Clinical Trial Simulations
AI in Drug Development · Recorded impact score: 3/5
Swiss biotech startup Atlas Bio emerged from stealth with a total of $12.5 million in funding to develop an AI foundation model for in-silico clinical trials. The Seed round of $10 million was led by Creandum, with participation from First Momentum Ventures and LEA Partners, who also led a previously undisclosed pre-Seed round of $2.5 million. The company's model, trained on 2 million human RNA readouts, simulates patient-level drug efficacy and safety, aiming to replace Phase II trials and animal testing. Atlas Bio is already working with a top-10 global pharma company and a Basel-based biotech client that has eliminated animal testing in a specific workflow. The founders, Simon Romanski and Sebastian Bayer, emphasize the potential to reduce drug development costs and timelines significantly.
- Atlas Bio raised a $10M Seed round led by Creandum, plus a $2.5M pre-Seed round led by First Momentum Ventures and LEA Partners, totaling $12.5M.
- The company's AI model is trained on roughly 2 million RNA readouts from human tissue.
Hiasynth raises angel funding for synthetic model of Europe's population
Market Intelligence · Recorded impact score: 2/5
Hiasynth, an AI startup, has raised an angel funding round led by Further Than Capital. The company built a synthetic model of Europe's population at 1:1 scale, containing half a billion personas across 37 countries, each with over 600 attributes that co-vary realistically. The model is queryable by AI through the Model Context Protocol (MCP), enabling any company to analyze European consumer markets without traditional research projects. The funding will support product development ahead of a planned seed round. Hiasynth launches in September 2026 at Bits & Pretzels in Munich. Emma Agering, founder, claims market intelligence prices will collapse as Europe becomes a single model. Further Than Capital's portfolio includes early positions in Lovable and Blackwall.
- Hiasynth raised an angel funding round led by Further Than Capital.
- The synthetic population model covers half a billion personas across 37 European countries.
Explore company relationships
Questions about Creandum
What is Creandum?
Creandum is an early-stage venture-capital firm investing in Seed and Series A technology companies.
Who uses Creandum?
Institutional limited partners invest in its funds, while early-stage technology founders receive capital and operating support.
How does Creandum make money?
It earns fund-management fees and carried interest on realised investment gains.
Sources & coverage
This profile uses public, official and technically observable information. Missing information does not prove that a product or relationship does not exist. The list below does not imply that every profile statement has been verified.
23 publicly documented primary sources and citations linked across the market graph.
Continue your research on Creandum
Open additional company details, personal Watchlists and your Strategic Intelligence Agent in Polaris7. It monitors your market daily and delivers tailored briefings with clear strategic context whenever relevant news occurs.
Daily intelligent monitoring · Verified primary sources.
Unlock full intelligence profile, ownership & live market signals